News

Filter

Current filters:

Heptares Therapeutics

1 to 9 of 11 results

Heptares meets milestone in MedImmune research collaboration

Heptares meets milestone in MedImmune research collaboration

23-01-2014

UK-based drug company Heptares Therapeutics has successfully completed the research phase of its antibody…

AstraZenecaBiotechnologyHeptares TherapeuticsMedImmuneResearchUK

Heptares appoints former GSK research head Tim Tasker as CMO

Heptares appoints former GSK research head Tim Tasker as CMO

10-01-2014

UK-based drug company Heptares Therapeutics has appointed Tim Tasker as chief medical officer and vice…

BoardroomHeptares TherapeuticsPharmaceuticalUK

Heptares gets first research milestone from Cubist

22-07-2013

UK GPCR drug discovery and development company Heptares Therapeutics says it has achieved the first research…

Cubist PharmaceuticalsFinancialHeptares TherapeuticsPharmaceuticalResearch

Oxford BioThera and Boehringer Ingelheim collaborate; Milestone for Heptares

29-04-2013

The UK's Oxford BioTherapeutics (OBT) and family-owned German drug major Boehringer Ingelheim have entered…

Boehringer IngelheimHeptares TherapeuticsLicensingNeurologicalOncologyOxford BioTherapeuticsPharmaceuticalResearchTakeda Pharmaceuticals

MorphoSys and Heptares collaborate to develop antibody therapeutics targeting GPCRs

13-02-2013

German biotech firm MorphoSys (FSE: MOR) and closely-held UK-based GPCR drug discovery company Heptares…

BiotechnologyHeptares TherapeuticsMorphoSysResearch

Cubist partners with Heptares on new medicines targeting GPCRs; provides 2012 business update

08-01-2013

UK-based Heptares Therapeutics, the leading GPCR drug discovery and development company, has signed an…

ceftolozaneCubist PharmaceuticalsFinancialGenito-urinaryHeptares TherapeuticsLicensingPharmaceuticalResearchtazobactam

Shire signs $190 million deal for preclinical CNS drug

21-03-2012

Ireland-headquartered drugmaker Shire (LSE: SHP) has exercised its exclusive option to license a novel…

Heptares TherapeuticsLicensingNeurologicalPharmaceuticalShire

AstraZeneca gains rights to Heptares GPCR drug for $6.25 million upfront

31-05-2011

Anglo-Swedish drug major AstraZeneca (LSE: AZN) revealed this morning that it has entered a four-year…

AstraZenecaDermatologicalsHeptares TherapeuticsLicensingNeurologicalPharmaceuticalResearch

1 to 9 of 11 results

COMPANY SPOTLIGHT

Menarini

Back to top